Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.